Collaboration to Pursue Cancer Diagnostics

(Burlington, NC, USA) has been selected by Becton, Dickinson (BD, Franklin Lakes, NJ, USA) to develop and commercialize molecular diagnostics and pharmacogenomic tests for cancer as part of the ongoing strategic alliance of BD and Millennium Pharmaceuticals, Inc. (Cambridge, MA, USA). The goal is to develop tests designed to provide individualized diagnostic and prognostic information, assist in treatment selection, and improve the prediction of patient health care outcomes.

TriPath will manage its activities for this development and commercialization effort through the creation of TriPath Oncology, Inc. The company will develop molecular diagnostic and pharmacogenomic tests for malignant melanoma and cancer of the prostate, breast, ovary, and cervix. These products will be based on genomic research conducted at Millennium under its agreement with BD.

"We believe that with TriPath Imaging's technology, Millennium's abilities in discovering molecular markers, and BD's experience in clinical diagnostics, we now have a team that can bring molecular diagnostic and pharmacogenomic tests to the market that will enhance cancer diagnostics and improve the practice of medicine,” said Vincent A. Forlenza, senior vice president of technology, strategy, and development for BD.




Related Links:
Millennium
TriPath
BD